The changing role of economic evaluation in valuing medical technologies
暂无分享,去创建一个
[1] J. Bridges. Lean Systems Approaches to Health Technology Assessment , 2006, PharmacoEconomics.
[2] A. Towse,et al. National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working? , 2012, PharmacoEconomics.
[3] R. Baltussen,et al. Priority setting of health interventions: the need for multi-criteria decision analysis , 2006, Cost effectiveness and resource allocation : C/E.
[4] Adrian Towse,et al. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? , 2010, British journal of clinical pharmacology.
[5] Finn Børlum Kristensen,et al. Involving stakeholders and developing a policy for stakeholder involvement in the European network for Health Technology Assessment, EUnetHTA , 2009, International Journal of Technology Assessment in Health Care.
[6] Stirling Bryan,et al. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. , 2007, Health economics.
[7] J. Hutton. 'Health Economics' and the evolution of economic evaluation of health technologies. , 2012, Health economics.
[8] A. Dhar,et al. National Institute for Health and Clinical Excellence , 2005 .
[9] A. Gandjour. Germany’s decision rule for setting ceiling prices of drugs , 2011, Applied health economics and health policy.
[10] N. Shear. Fulfilling an Unmet Need in Psoriasis , 2006, Drug safety.
[11] Dana Goldman,et al. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. , 2010, Health economics.
[12] Stephen Joel Coons,et al. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.
[13] Clifford Goodman,et al. Society for Medical Decision Making , 1988 .
[14] Steven Wooding,et al. Assessing the impact of health technology assessment in the Netherlands , 2008, International Journal of Technology Assessment in Health Care.
[15] M Ryan,et al. Eliciting public preferences for healthcare: a systematic review of techniques. , 2001, Health technology assessment.
[16] J. Singh. International society for pharmacoeconomics and outcomes research , 2006 .
[17] J Raftery. Methodological limitations of cost-effectiveness analysis in health care: implications for decision making and service provision. , 1999, Journal of evaluation in clinical practice.
[18] A. Gafni,et al. The 'NICE' Approach to Technology Assessment: An Economics Perspective , 2004, Health care management science.
[19] John Harris,et al. It’s not NICE to discriminate , 2005, Journal of Medical Ethics.
[20] M. Drummond,et al. IMPLEMENTING THE FINDINGS OF HEALTH TECHNOLOGY ASSESSMENTS , 2000, International Journal of Technology Assessment in Health Care.
[21] Joshua T. Cohen,et al. When is evidence sufficient? , 2005, Health affairs.
[22] Jon Strand,et al. The relationship between property values and railroad proximity: a study based on hedonic prices and real estate brokers' appraisals , 2001 .
[23] M. Frommer,et al. Criteria for evaluating evidence on public health interventions , 2002, Journal of epidemiology and community health.
[24] Mita Giacomini,et al. Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice. , 2007, Health policy.
[25] S. Palmer,et al. Incorporating option values into the economic evaluation of health care technologies. , 2000, Journal of health economics.
[26] V. Suslow. Are there better ways to spell relief? : a hedonic pricing analysis of ulcer drugs , 1992 .
[27] Maarten J. IJzerman,et al. Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences , 2011, International Journal of Technology Assessment in Health Care.
[28] Maarten Joost IJzerman,et al. A Comparison of Analytic Hierarchy Process and Conjoint Analysis Methods in Assessing Treatment Alternatives for Stroke Rehabilitation , 2012, The Patient - Patient-Centered Outcomes Research.
[29] M. Gagnon,et al. Introducing patients' and the public's perspectives to health technology assessment: A systematic review of international experiences , 2011, International Journal of Technology Assessment in Health Care.
[30] Charles E. Cunningham,et al. Providing Information to Parents of Children with Mental Health Problems: A Discrete Choice Conjoint Analysis of Professional Preferences , 2009, Journal of abnormal child psychology.
[31] A Gafni,et al. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? , 1992, Journal of health economics.
[32] R. Smith. NICE: a panacea for the NHS? , 1999, BMJ.
[33] Mandy Ryan,et al. Using discrete choice experiments to value health care programmes: current practice and future research reflections. , 2003, Applied health economics and health policy.
[34] Ken J Harvey. The Pharmaceutical Benefits Scheme 2003–2004 , 2005, Australia and New Zealand health policy.
[35] Y. Bombard,et al. Eliciting ethical and social values in health technology assessment: A participatory approach. , 2011, Social Science & Medicine (1967).
[36] F. Collins,et al. Patient-Centered Outcomes Research Institute: The Intersection of Science and Health Care , 2010, Science Translational Medicine.
[37] Guillermo A. Mendoza,et al. Multi-criteria decision analysis in natural resource management: A critical review of methods and new modelling paradigms , 2006 .
[38] Richard J. Zeckhauser,et al. The economics of catastrophes , 1996 .
[39] Pekka Korhonen,et al. Multiple criteria decision support - A review , 1992 .
[40] T. Seager,et al. Multi-Criteria Decision Analysis: A Framework for Structuring Remedial Decisions at Contaminated Sites , 2004 .
[41] Jing Jing Li,et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.
[42] Deborah Schrag,et al. The price tag on progress--chemotherapy for colorectal cancer. , 2004, The New England journal of medicine.
[43] Howard L Zwibel,et al. Improving quality of life in multiple sclerosis: an unmet need. , 2011, The American journal of managed care.
[44] J. Bridges,et al. Identifying patient-relevant endpoints among individuals with schizophrenia: An application of patient-centered health technology assessment , 2009, International Journal of Technology Assessment in Health Care.
[45] Bryn Williams-Jones,et al. Mapping the integration of social and ethical issues in health technology assessment , 2007, International Journal of Technology Assessment in Health Care.
[46] M. Weinstein,et al. Medicare and cost-effectiveness analysis. , 2005, The New England journal of medicine.
[47] Emily Lancsar,et al. Discrete choice experiments to measure consumer preferences for health and healthcare , 2002, Expert review of pharmacoeconomics & outcomes research.
[48] Murray D. Krahn,et al. INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT , 2014 .
[49] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[50] L. Gulácsi,et al. Health economics and health technology assessment in Central and Eastern Europe: a dose of reality , 2012, The European Journal of Health Economics.
[51] T. L. Saaty. A Scaling Method for Priorities in Hierarchical Structures , 1977 .
[52] A. Coulter. Perspectives on health technology assessment: response from the patient's perspective , 2004, International Journal of Technology Assessment in Health Care.
[53] J. Eisenberg,et al. Ten lessons for evidence-based technology assessment. , 1999, JAMA.
[54] D. Weedon. Health technology assessment in Australia , 1999, The Medical journal of Australia.
[55] J. Zivin,et al. Addressing risk preferences in cost-effectiveness analyses. , 2002, Applied health economics and health policy.
[56] J. Bridges. What can economics add to health technology assessment? Please not just another cost-effectiveness analysis! , 2006, Expert review of pharmacoeconomics & outcomes research.
[57] Dorte Gyrd-Hansen,et al. International comparison of the definition and the practical application of health technology assessment , 2005, International Journal of Technology Assessment in Health Care.
[58] J. Bridges,et al. Condom avoidance and determinants of demand for male circumcision in Johannesburg, South Africa. , 2011, Health policy and planning.
[59] Falls Church,et al. HTA 101 INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT , 2004 .
[60] Carin A Uyl-de Groot,et al. Incorporating equity-efficiency interactions in cost-effectiveness analysis-three approaches applied to breast cancer control. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[61] K. Chalkidou,et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. , 2009, The Milbank quarterly.
[62] D. Hailey. Development of the International Network of Agencies for Health Technology Assessment , 2009, International Journal of Technology Assessment in Health Care.
[63] Joseph T Sobota,et al. Orphan Drug Act , 1990 .
[64] S. Goodman,et al. The methods of comparative effectiveness research. , 2012, Annual review of public health.
[65] R. Fitzpatrick,et al. Qualitative methods for assessing health care. , 1994, Quality in health care : QHC.
[66] R. Steinbrook. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. , 2008, The New England journal of medicine.
[67] M. Sculpher,et al. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods. , 2010, Health economics.
[68] Deborah Marshall,et al. Conjoint Analysis Applications in Health — How are Studies being Designed and Reported? , 2010, The patient.
[69] A. Gafni,et al. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. , 2002, Health economics.
[70] M. Nasser,et al. Institute for Quality and Efficiency in Health Care: Germany. , 2009, Issue brief.
[71] Christopher Freeman,et al. The economics of innovation , 1985 .
[72] J. Strough,et al. Decision‐making heuristics and biases across the life span , 2011, Annals of the New York Academy of Sciences.
[73] Elizabeth T. Kinter,et al. Things are Looking up Since We Started Listening to Patients , 2008, The patient.
[74] K. Lancaster. A New Approach to Consumer Theory , 1966, Journal of Political Economy.
[75] S. Grosse. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold , 2008, Expert review of pharmacoeconomics & outcomes research.
[76] C. Mitton,et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom. , 2006, Health affairs.
[77] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[78] M. Niezen,et al. The Increasingly Complex Fourth Hurdle for Pharmaceuticals , 2007, PharmacoEconomics.
[80] W. Brouwer,et al. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. , 2002, Health policy.
[81] M. Drummond,et al. PRIORITIZING INVESTMENTS IN HEALTH TECHNOLOGY ASSESSMENT , 2000, International Journal of Technology Assessment in Health Care.
[82] Hengjin Dong. Methods of Economic Evaluation for the German Statutory Healthcare System , 2012, PharmacoEconomics.
[83] Steven D Pearson,et al. Quality, innovation, and value for money: NICE and the British National Health Service. , 2005, JAMA.
[84] A. Gafni,et al. Information created to evade reality (ICER): things we should not look to for answers. , 2006, PharmacoEconomics.
[85] M. Ryan,et al. A ROLE FOR CONJOINT ANALYSIS IN TECHNOLOGY ASSESSMENT IN HEALTH CARE? , 1999, International Journal of Technology Assessment in Health Care.
[86] The Works and Correspondence of David Ricardo , 1952 .
[87] F. Schubert. HEALTH TECHNOLOGY ASSESSMENT , 2002, International Journal of Technology Assessment in Health Care.
[88] D. Menon,et al. HEALTH TECHNOLOGY ASSESSMENT IN CANADA , 2000, International Journal of Technology Assessment in Health Care.
[89] Stuart Peacock,et al. Social welfare and the Affordable Care Act: is it ever optimal to set aside comparative cost? , 2012, Social science & medicine.
[90] John F. P. Bridges,et al. Future challenges for the economic evaluation of healthcare , 2012, PharmacoEconomics.
[91] Scott D Ramsey,et al. Health technology assessment in health-care decisions in the United States. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[92] A Briggs,et al. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.
[93] S. Rosen. Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition , 1974, Journal of Political Economy.
[94] P. Danzon,et al. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. , 2011, Health affairs.
[95] C. McCabe,et al. Orphan drugs and the NHS: should we value rarity? , 2005, BMJ : British Medical Journal.
[96] Steven D. Pinkerton,et al. Ethical Issues in Cost-Effectiveness Analysis. , 2002 .
[97] A. Hauber. Healthy-years equivalent: wounded but not yet dead , 2009, Expert review of pharmacoeconomics & outcomes research.
[98] John Stuart Mill,et al. Principles of Political Economy: With Some of Their Applications to Social Philosophy , 2000 .
[99] Richard E. Caves,et al. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .
[100] R N Battista,et al. The evolving paradigm of health technology assessment: reflections for the millennium. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[101] T. Flynn. Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling , 2010, Expert review of pharmacoeconomics & outcomes research.
[102] Elias Mossialos,et al. Health technology assessment and its influence on health-care priority setting , 2004, International Journal of Technology Assessment in Health Care.
[103] P. Dolan,et al. Valuing health states: a comparison of methods. , 1996, Journal of health economics.
[104] J. Wennberg,et al. Outcomes research, cost containment, and the fear of health care rationing. , 1990, The New England journal of medicine.
[105] J. Louviere,et al. Conducting Discrete Choice Experiments to Inform Healthcare Decision Making , 2012, PharmacoEconomics.
[106] Andrew Lloyd,et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[107] R. Busse,et al. Analysing the impact of health-care system change in the EU member states--Germany. , 2005, Health economics.
[108] David Hailey,et al. TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT , 2003, International Journal of Technology Assessment in Health Care.
[109] Henry G. Grabowski,et al. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.
[110] J. Bridges,et al. International experience with comparative effectiveness research: case studies from England/Wales and Germany. , 2010, Advances in health economics and health services research.
[111] Hanane Khoury,et al. Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA) , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[112] C. Teljeur,et al. ENDPOINTS FOR RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS , 2014, International Journal of Technology Assessment in Health Care.
[113] D. Webb,et al. Scottish Medicines Consortium: an Overview of Rapid New Drug Assessment in Scotland. , 2007, Scottish medical journal.
[114] John P. A. Ioannidis,et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. , 2012, JAMA.
[115] M. Aristides,et al. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. , 2002, PharmacoEconomics.
[116] D. Menon,et al. Role of patient and public participation in health technology assessment and coverage decisions , 2011, Expert review of pharmacoeconomics & outcomes research.
[117] J. Hiller,et al. Exploring policy-makers’ perspectives on disinvestment from ineffective healthcare practices , 2008, International Journal of Technology Assessment in Health Care.
[118] M. Koopmanschap,et al. Process utility from providing informal care: the benefit of caring. , 2005, Health policy.
[119] Uwe Siebert,et al. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden , 2009, International Journal of Technology Assessment in Health Care.
[120] C. Antonelli. The Economics of Innovation, New Technologies and Structural Change , 2002 .
[121] Chris Henshall,et al. USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT” , 2012, International Journal of Technology Assessment in Health Care.
[122] Adam Smith,et al. An Inquiry into the Nature and Causes of the Wealth of Nations: A Selected Edition , 2008 .
[123] D. Rennie,et al. Pharmacoeconomic analyses: making them transparent, making them credible. , 2000, JAMA.
[124] W. Brouwer,et al. The efficiency frontier approach to economic evaluation: will it help German policy making? , 2010, Health economics.
[125] D. Banta. The development of health technology assessment. , 2003, Health policy.
[126] John F P Bridges,et al. Things are Looking up Since We Started Listening to Patients: Trends in the Application of Conjoint Analysis in Health 1982-2007. , 2008, The patient.
[127] J. Richardson,et al. Preferences for the normative basis of health care priority setting: some evidence from two countries. , 2013, Health Economics.
[128] P. Shackley,et al. Does "process utility" exist? A case study of willingness to pay for laparoscopic cholecystectomy. , 1997, Social science & medicine.
[129] J. Robertson,et al. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. , 2009, Australian health review : a publication of the Australian Hospital Association.
[130] Matthew J. Liberatore,et al. The analytic hierarchy process in medical and health care decision making: A literature review , 2008, Eur. J. Oper. Res..
[131] J. Bridges,et al. Using comparative effectiveness research to inform decision-making: is there a role of economic evaluation? , 2012, Journal of comparative effectiveness research.
[132] W. Reekie. Price and Quality Competition in the United States Drug Industry , 1978 .
[133] D. Feeny,et al. The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.
[134] C. Mullins,et al. Healthcare Rationing by Proxy , 2012, PharmacoEconomics.
[135] S. Hawley. Conjoint analysis: a 'new' way to evaluate patients' preferences. , 2008, The patient.
[136] John F P Bridges,et al. Patient-based health technology assessment: A vision of the future , 2007, International Journal of Technology Assessment in Health Care.
[137] C. Donaldson,et al. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism? , 2003, Social science & medicine.
[138] Jill Sage,et al. The Patient-Centered Outcomes Research Institute. , 2014, Bulletin of the American College of Surgeons.
[139] Karl Claxton,et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence , 2007, Journal of health services research & policy.